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A one-electron reductive metabolism of 1,Zdibromoethane (DBE) is described that gives rise to a free 
radical intermediate, which can be stabilized by a spin trapping agent and detected by electron spin 
resonance spectroscopy. Using rat liver microsomes or isolated hepatocytes from phenobarbitone 
pretreated animals, under hypoxic conditions, it has been possible to trap a free radical intermediate and 
identify it by using 13C-DBE. Inhibition experiments have demonstrated that the site of activation is the 
microsomal drug metabolizing system. 
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1. INTRODUCTION 
1,2_Dibromoethane (DBE) is a synthetic chemi- 
cal used primarily in antiknock additives to petrol; 
other uses include pesticidal fumigation of stored 
grain, vegetables and fruits, and preplanting treat- 
ment of soil to protect against nematodes [1,2]. 
Reports of the high toxicity of DBE for animals 
and humans appeared a number of years ago 
[3-51. DBE produces respiratory lesions in rats 
and mice [6,7]; abnormal spermatogenesis in bulls 
[8,9] and in rams [lo]; is carcinogenic in rodents 
[2,11]; is a mutagen in microorganisms [ 12,131 and 
in mammalian cells, both in the absence or in the 
presence of a metabolizing system [ 141. The effects 
of chronic exposure in man are not certain al- 
though abnormal spermatogenesis and several 
cases of cancer have been reported [15] following 
industrial exposure. 
The metabolism of DBE has been studied both 
in vivo and in vitro [ 16- 181. Two main pathways 
have been suggested: one involves a glutathione 
transferase-mediated conjugation of DBE with 
glutathione (GSH), which eventually results in the 
formation of mercapturic acid derivatives; the 
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other is based on the oxidative dehalogenation by 
microsomal enzymes, resulting in bromoacetalde- 
hyde. However, by analogy with other halogenated 
compounds such as CC4 and CBrCIs and halo- 
thane [19,20], a cytochrome PUO-mediated one- 
electron reduction of 1,2_dibromoethane can be 
postulated that will give rise to a free radical inter- 
mediate. Such free radicals can often be detected 
by electron spin resonance (ESR) spectroscopy 
associated with the spin trapping technique [21], 
where the free radical interacts with a spin trap 
possessing a nitrone functional group to form a 
comparatively long-lived nitroxide radical adduct. 
We now report on the existence of a one-electron 
reductive pathway for DBE, under hypoxic condi- 
tions, resulting in the formation of a free radical 
intermediate and on its positive identification using 
the spin trapping technique and [ 13C] DBE. 
2. MATERIALS AND METHODS 
1,2-DBE (C. Erba, Milano) was redistilled before 
use; [13C]DBE was obtained from Merk, Sharp 
and Dohme Limited (Canada); phenyl-t-butyl- 
nitrone (PBN) was purchased from Aldrich Chemi- 
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cal Co. (Milwaukee WI); collagenase (type I) was 
supplied by Sigma Chemical Co. (Poole, Dorset); 
other reactants of the highest commercial grade 
were used without further purification. 
Male Wistar rats, maintained on a standard 
laboratory diet and water ‘ad libitum’ were used 
for all the experiments. Phenobarbitone (PB), 
when required, was administered in drinking water 
at 1 g/l for 5 days before the experiment. 
Rat hepatocyte suspensions were prepared as in 
[22]. Samples (1.5 ml) of the suspension containing 
10’ cells/ml were incubated in the presence of the 
spin trapping agent (PBN 25 mM) at 37°C for 
15 min in stoppered (50 ml) Erlenmeyer flasks that 
had central wells. Microsomes were prepared as in 
[23]. DBE was added in the central well of the 
Erlenmeyer flasks. Hypoxic conditions were ob- 
tained by gentle blowing of oxygen-free nitrogen 
on the suspension for 10min before adding DBE. 
The oxygen concentration was measured using a 
Clark-type electrode. Differential spectra were re- 
corded using a DU 8 Beckman spectrophotometer . 
A Varian Associates E4 spectrometer, fitted 
with a variable temperature cavity was used for the 
ESR analysis as in [20]. Gas-liquid chromatogra- 
phic analyses were carried out on a Varian 3600 
gas-liquid chromatograph, fitted with a flame 
ionisation detector and using a 80/100 carbopack 
C/O. 1% SP 1000 column (Supelco); detector and 
injector temp. 200°C; oven temp. 120°C. 
3. RESULTS AND DISCUSSION 
Aerobic incubation of rat liver hepatocytes in 
the presence of PBN 25 mM and DBE at 37°C did 
not give rise to any radical adduct (fig.lb). When 
the same kind of incubation was performed under 
hypoxic conditions using hepatocytes from pheno- 
barbitone induced rats, a radical adduct was de- 
tected by ESR (fig.lc). The spectrum shows a 
triplet of doublets, the hyperfine splitting con- 
stants were aN = 14.5 G and aH = 2.15G. The 
same spectrum was obtained from microsomal sus- 
pensions. 
These data are not sufficient for the assignment 
of the above spectrum to the DBE free radical 
species, therefore [13C]EDB was used instead of 
[“CIDBE. 
The paramagnetic carbon-13 nucleus (S = l/2) 
gives rise to a splitting of the spectrum lines when 
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Fig.1. ESR spectra obtained from isolated rat hepato- 
cytes incubated at 37°C for 15 min in the presence of the 
spin trapping agent PBN. (a) no addition of DBE; (b) 
hepatocytes in normoxic conditions, with DBE (2.54) 
added to the central well; (c) hepatocyte suspension 
under hypoxic conditions, with DBE (2.54) added to 
the central well; (d) as (c), but after adding [13C]DBE, 
90% of 13C, (2.5~1) to the central well. 
it reacts with the spin trapping agent and is located 
P to the nitroxide group. Fig.ld shows the effect of 
the introduction of [ 13C]DBE in the incubation mix- 
ture; the characteristic hyperfine splitting, a13c = 
9.2 G clearly indicates that the radical species trap- 
ped is indeed the DBE-derived free radical. The 
hyperfine splitting effect due to 13C was propor- 
tional to the atom % of 13C relative to “C in the 
DBE added to the system. Oxygen was <20pM at 
the beginning of the incubation time and was re- 
duced below 1pM after about 5 min incubation. 
The effects on the signal intensity by varying the 
amount of DBE added to hepatocytes and micro- 
somes suspension are shown in fig.2. In both the 
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Fig.2. (a) Concentration of DBE in the hepatocyte sus- 
pension increases with the amount of DBE added to the 
central well. (0) Intensity of the ESR signal (arbitrary 
units) increases the increase of DBE added to the central 
well. Mean values +SEM are shown. 
experimental systems the intensity of the DBE- 
derived adduct is directly proportional to the 
amount of DBE added. 
Hepatocytes and rnicrosomes prepared from rats 
that had not been induced with PB or from 3- 
methylcholantrene-pretreated rats did not give any 
appreciable radical adduct formation. 
To determine the final concentration of DBE in 
the incubation mixture, gas-liquid chromatogra- 
phic analysis has been carried out on the suspen- 
sions. The use of Carbopack C allowed the direct 
introduction of the cell suspension into the column, 
without any previous distillation or extraction in 
organic solvent. Fig.2 shows the linear relationship 
between the increase of DBE added in the central 
well and the rise in DBE concentration found at 
10 min incubation. 
Double beam differential spectroscopy [24] of 
DBE was carried out on phenobarbitone-pretreated 
rat microsomes and showed type I spectra, both 
under aerobic and anaerobic conditions, with a 
trough at 420nm and a peak at 391 nm. 
Experiments with cytochrome P450 inhibitors 
such as SKF 525A, metyrapone, p-chloromercuri- 
benzoate (p-CMB) and carbon monoxide demon- 
strated a decrease in the radical adduct formation, 
carbon monoxide being the most effective (fig.3). 
The stimulation produced by pretreatment with 
phenobarbitone, the formation of type I spectra, 
and the effect of the inhibitors imply the involve- 
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Fig.3. Effects of various inhibitors of the microsomal 
drug metabolizing system on the formation of DBE-de- 
rived free radical with PBN arbitrary units. For each 
inhibitor the number of experiments was = 4. The stan- 
dard error of the mean has been reported on each bar of 
the plot. (A) Microsomes incubated with DBE (2.5~1 in 
the central well); (B*) addition of methyrapone (0.5 mM); 
(Co) addition of SKF 525 A (0,s mM); (D) addition of 
p-chloromercuribenzoate; (E”) addition of carbon mon- 
oxide (1 min flow); (*) significatively different from A 
(p < 0.05); (“) significatively different from A 
(p < 0.005). 
ment of the cytochrome P450 in the radical activa- 
tion of DBE; the drug metabolizing system per- 
forming a one-electron reduction of the compound 
and a consequent dehalogenation with the forma- 
tion of the free radical HzCBr-H2C’ or 
HsC-HCBi). The low oxygen concentration is de- 
cisive for a significant reductive type of metabo- 
lism. With similar conditions a reductive dehalo- 
genation mechanism involving a radical-ferric 
cytochrome complex has been reported for 
chlorinated alkanes [25]. 
Taking into account that, under physiological 
conditions, the average hepatic oxygen concentra- 
tion is about 35/M, and that the presence of an 
intrahepatic oxygen gradient is well established, a 
reductive type of metabolic activation of DBE may 
be possible even with a normal blood oxygen supply 
to the liver in vivo [26,27]. 
These data clearly demonstrate the presence of a 
new metabolic pathway for DBE. Further studies 
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are needed for the determination of the reactivity 
of the radical intermediate and its relevance to the 
toxicity and carcinogenicity of the parent mole- 
cule. 
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